Get the Stockscreener App
7.64
7.91%
0.56
Bioventus Inc stock is traded at $7.64, with a volume of 603.87K.
It is up +7.91% in the last 24 hours and up +18.63% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$7.08
Open:
$7.17
24h Volume:
603.87K
Relative Volume:
1.41
Market Cap:
$511.06M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-12.73
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
+3.66%
1M Performance:
+18.63%
6M Performance:
-23.68%
1Y Performance:
-22.67%
1-Day Range:
$7.08
$7.74
1-Week Range:
$7.0301
$7.74
52-Week Range:
$5.81
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.64 | 480.29M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
RSI Reset May Fuel Rebound in Bioventus Inc.Portfolio Performance Report & Verified Entry Point Detection - kangso.co.kr
What makes Bioventus Inc. stock price move sharplyQuarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Regression analysis insights on Bioventus Inc. performance2025 AllTime Highs & Safe Capital Growth Tips - Newser
Is it time to cut losses on Bioventus Inc.Earnings Recap Summary & Weekly High Return Stock Opportunities - Newser
Is Bioventus Inc. reversing from oversold territoryQuarterly Market Summary & High Accuracy Swing Entry Alerts - Newser
How to forecast Bioventus Inc. trends using time series2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Analyzing Bioventus Inc. with risk reward ratio chartsTrade Ideas & Low Risk Investment Opportunities - Newser
Why Bioventus Inc. stock attracts strong analyst attentionMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
Bioventus Inc. stock outlook for YEARJuly 2025 Recap & AI Based Trade Execution Alerts - Newser
What recovery options are there for Bioventus Inc.July 2025 Institutional & High Accuracy Buy Signal Tips - Newser
Is Bioventus Inc. Forming a Bottom PatternJuly 2025 EndofMonth & Community Consensus Stock Picks - Newser
Detecting support and resistance levels for Bioventus Inc.July 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Tick level data insight on Bioventus Inc. volatilityJuly 2025 PreEarnings & Verified Momentum Stock Watchlist - Newser
Published on: 2025-08-17 22:56:17 - Newser
Risk vs reward if holding onto Bioventus Inc.2025 Top Gainers & Safe Entry Momentum Tips - Newser
How to use Fibonacci retracement on Bioventus Inc.July 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
Should you hold or exit Bioventus Inc. nowMarket Performance Summary & Daily Entry Point Alerts - Newser
Can a trend reversal in Bioventus Inc. lead to recovery2025 Top Decliners & Free Risk Controlled Daily Trade Plans - Newser
Real time pattern detection on Bioventus Inc. stock2025 Top Gainers & Daily Chart Pattern Signal Reports - Newser
How to monitor Bioventus Inc. with trend dashboards2025 Trade Ideas & Fast Gain Stock Tips - Newser
Advanced analytics toolkit walkthrough for Bioventus Inc.Forecast Cut & Real-Time Volume Spike Alerts - Newser
Tools to monitor Bioventus Inc. recovery probabilityQuarterly Profit Summary & Smart Money Movement Alerts - Newser
Is Bioventus Inc. stock entering bullish territoryJuly 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - Newser
What moving averages say about Bioventus Inc.Quarterly Profit Review & Community Driven Trade Alerts - Newser
Competitive Positioning of Bioventus Inc.: Is It Leading or Lagging2025 Momentum Check & Weekly Return Optimization Alerts - Newser
We Think Bioventus' (NASDAQ:BVS) Robust Earnings Are Conservative - simplywall.st
Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT - MSN
Shareholders Can Be Confident That Bioventus' (NASDAQ:BVS) Earnings Are High Quality - ca.finance.yahoo.com
New Product Launches: Will They Boost Bioventus Inc. Stock in 2025Quarterly Trade Report & AI Forecasted Entry and Exit Points - Newser
Is Bioventus (NASDAQ:BVS) A Risky Investment? - 富途牛牛
Bioventus: Strategic Initiatives and Growth Prospects Drive Buy Rating - TipRanks
Bioventus (NASDAQ:BVS) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Bioventus Inc.’s Price Action Aligns with Quant Signals [July 2025 Technicals]Free Growth-Oriented Investment Plans - sundaytimes.kr
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Bioventus at Canaccord Conference: Strategic Growth Path By Investing.com - Investing.com Australia
Bioventus at Canaccord Conference: Strategic Growth Path - Investing.com
Cantor Fitzgerald Reaffirms Their Buy Rating on Bioventus (BVS) - The Globe and Mail
Bioventus to Present at Canaccord Genuity Global Growth Conference on August 12, 2025. - AInvest
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Bioventus stock - Investing.com
Bioventus Inc. Crosses 200 Day MA — Signal or NoiseTarget Return Focused Trade Insights Shared - metal.it
Bioventus Earnings Call: Strong Growth and Resilience - TipRanks
Should Investors Capitalize on Bioventus' Earnings Outperformance Amid Industry Lags? - AInvest
Bioventus Inc. Just Recorded A 154% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Bioventus Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Yahoo Finance
Bioventus Inc. (NASDAQ:BVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Bioventus outlines path to $100M+ PNS revenue opportunity as new products receive clearance - MSN
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - The Manila Times
Bioventus Q2 Earnings Call: Robust Growth and Strategic Resilience - AInvest
Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $15 - 富途牛牛
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bioventus Inc Stock (BVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bartholdson John A. | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
72,045 |
| SUTTER MARTIN P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| STALNECKER SUSAN M | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
105,957 |
| NOHRA GUY P | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
126,610 |
| NEELS GUIDO J | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
85,241 |
| McMurry-Heath Michelle | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
74,698 |
| Ladone Mary Kay | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
78,981 |
| HAWKINS WILLIAM A | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
257,851 |
| Beyer Pat | Director |
Jun 02 '25 |
Option Exercise |
0.00 |
26,493 |
0 |
76,436 |
| Singleton Mark Leonard | SVP & CFO |
Apr 11 '25 |
Sale |
7.57 |
3,875 |
29,334 |
141,088 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):